Skip to main navigation
  • Careers
  • Contact

Menu

Skip to content
  • Company
    • Our Vision & Mission
    • Our People
    • Our Leadership
    • Board of Directors
    • Manufacturing
    • Affiliations
  • Investors
    • News & Events
      • Events Calendar
      • Presentations
    • Financials
      • SEC Filings
    • Stock
      • Historical Price Lookup
      • Investment Calculator
      • Ownership Summary
      • Estimates
    • Governance
      • Board of Directors
      • Committee Composition
    • Shareholder Services
      • Email Alerts
  • Pipeline
  • Platforms
    • Immuno-Oncology Assets
      • G-MABs™
      • CAR-T
      • ADCs
      • iTAbs
      • Oncolytic Virus
    • Pain Management Assets
      • ZTlido™
      • RTX
  • Translational Efficiencies

News Releases

fundamentals sub menu

  • Fundamentals

Scilex Announces Pricing and Availability of ZTlido™ for the Commercial Launch of its First Product in October of 2018

Sep 19, 2018

Sorrento Therapeutics Subsidiary, Scilex, Raises $140 million in Non-Dilutive Royalty-Based Financing to Support the Commercialization of Non-Opioid ZTlido™ Pain Medication

Sep 10, 2018

Sorrento Therapeutics to Present at FB Riley and HC Wainwright Sept 2018 Healthcare Conferences in NYC (NY)

Sep 02, 2018

1st Patient Treated for Osteoarthritis Knee Pain in Sorrento Resiniferatoxin Phase 1B Trial Meets Both Safety and Efficacy Expectations

Aug 13, 2018

Sorrento Acquires the Sofusa™ Lymphatic Delivery Platform for Immune-Oncology (I-O) Antibody Therapeutics

Jul 03, 2018

Sorrento Therapeutics issues Chairman/CEO corporate update to stockholders

Jun 14, 2018

Sorrento Therapeutics CEO Dr. Henry Ji Invited to the Fourth International Vatican Conference on “Unite to Cure”

Apr 23, 2018

Sorrento and Celularity to Start Anti-CD38 CAR-T Phase 1 Clinical Trial in Patients With Relapsed or Refractory Multiple Myeloma (NCT03464916)

Apr 05, 2018

Sorrento Therapeutics to Present at H.C. Wainwright Global Lifesciences Conference 04/09/18

Apr 04, 2018

Sorrento Therapeutics Chairman/CEO update to stockholders

Mar 28, 2018

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Next page next ›
  • Last page last »

Tools

  • Print Page
  • Email Alerts
  • RSS Feeds
  • Email Page
Clinical Trials
clinicaltrials@sorrentotherapeutics.com
Investors
investors@sorrentotherapeutics.com
Business Development
business@sorrentotherapeutics.com
Media Requests
mediarelations@sorrentotherapeutics.com
© 2017 Sorrento Therapeutics, Inc. All Rights Reserved.
  • Terms of Use
  • Privacy Policy
  • DMCA
  • Trademarks
  • Linking Policy
  • LinkedIn
MENU
  • Company
    • Our Vision & Mission
    • Our People
    • Our Leadership
    • Board of Directors
    • Manufacturing
    • Affiliations
  • Investors
    • Stock
      • Historical Price Lookup
      • Investment Calculator
      • Ownership Summary
      • Analyst Coverage
      • Estimates
    • News & Events
      • Events Calendar
      • Presentations
    • Financials
      • Quarterly Results
      • Fundamentals
    • Governance
      • Board of Directors
      • Committee Composition
    • Shareholder Services
      • Investor Contact
      • Email Alerts
  • Pipeline
  • Platforms
    • Immuno-Oncology Assets
      • G-MABs™
      • CAR-T
      • Antibody Drug Conjugates (ADCs)
      • iTAbs
      • Oncolytic Virus
    • Pain Management Assets
      • RTX
      • ZTlido™
  • Translational Efficiencies
  • Careers
  • Contact